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We recently reported that myocardial stretch induces the activation of the mineralocorticoid receptor (MR).1 
This conclusion was based on the prevention of some of the 
stretch-triggered consequences by 2 different MR inhibitors, 
spironolactone and eplerenone. These compounds canceled the 
stretch-induced activation of redox-sensitive kinases upstream 
of the Na+/H+ exchanger (NHE1), as well as the increase in 
NHE1 phosphorylation and its mechanical counterpart, the 
slow force response (SFR).1–3 Previous studies demonstrated 
that inhibiting the NHE1 either pharmacologically or by 
silencing its expression also prevents these stretch-triggered 
actions2–4 and decreases the production of mitochondrial reac-
tive oxygen species (ROS).5,6 However, pharmacological inhi-
bition is not always deprived of nonspecific unwanted effects. 
Spironolactone is a nonselective compound that also blocks 
receptors other than the MR.7 Furthermore, both spironolac-
tone and eplerenone have been described as having an inverse 
agonist activity on the MR.8 Therefore, we examined whether 
conclusive evidence about MR activation after myocardial 
stretch could be obtained using biomolecular techniques to 
silence MR expression in rat hearts. For this purpose, we took 
advantage of the RNA interference technique that we recently 
used to successfully blunt NHE1 expression in the rat myocar-
dium.4 Thus, small hairpin interfering RNA directed against 
the MR was incorporated into a lentiviral vector (l-shMR) and 
injected into the left ventricular wall of adult Wistar rats. One 
month later, the effect of stretching papillary muscles on the 
activation of redox-sensitive kinases, NHE1 activity, and SFR 
development, as well as the upstream signals mediating the 
increase in myocardial ROS production, was analyzed. Herein, 
we provide evidence supporting that myocardial stretch acti-
vates the MR, this step being critical for promoting the redox-
sensitive kinase–mediated NHE1 stimulation. A preliminary 
report of our data has been presented elsewhere.9
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Materials and Methods
All procedures followed during this investigation conform to the 
Guide for the Care and Use of Laboratory Animals published by the 
US National Institutes of Health (Publication No. 85-23, revised 1996) 
and to the guidelines laid down by the Animal Welfare Committee of 
La Plata School of Medicine. Small hairpin interfering RNA capable 
of mediating specific MR knockdown was incorporated into a len-
tiviral vector (l-shMR) and injected into the left ventricular wall of 
Wistar rats. A lentiviral vector expressing a nonsilencing sequence 
(scramble) was used as control. A complete Materials and Methods 
section, including the detailed procedure to generate the interference 
RNA and inject this into the ventricular wall, is detailed in the online-
only Data Supplement. That section also includes the methodology 
used to determine myocardial MR mRNA and protein expression, 
myocardial DsRed fluorescence by confocal microscopy, the stretch-
triggered activation of the redox-sensitive kinases ERK1/2 and p90RSK, 
the NHE1-mediated changes in pH
i
, the SFR, and the ROS production.
Results
Lentivirus coding for the small hairpin interfering RNA-MR/
DsRed (l-shMR) or the small hairpin interfering RNA-
scramble sequence/dsRED (control) was injected into the rat 
myocardium at 2 sites in the left ventricular free wall near the 
cardiac apex, and rats were euthanized 1 month later. To check 
the spreading of the lentivirus, we measured DsRed fluores-
cence by confocal microscopy in the cardiac tissue from the 
site of injection to papillary muscles from l-shMR–injected, 
scramble-injected, and sham-operated (no injections) rats. 
A patchy red fluorescence distribution was observed in both 
groups of lentivirus-injected hearts, whereas no signal was 
detected in the sham-operated group (Figure 1). Magnified 
images highlighting the presence of DsRed inside the myo-
cardial cells in a fascicular-like distribution pattern are shown 
in Figure S2 in the online-only Data Supplement.
MR protein expression measured in cardiac homogenates of 
the left ventricular myocardium, as well as in isolated papil-
lary muscles, revealed that hearts injected with l-shMR had 
an ≈45% reduction in receptor expression compared with the 
control-injected hearts (P<0.05; Figure 2A and 2B). This result 
indicates that the small interfering RNA directed against the 
MR had spread throughout the ventricular myocardium from 
the sites of injection, as suggested by the confocal images 
shown in Figure 1. The injection of l-shMR did not modify the 
myocardial expression of either GAPDH (control: 100.1±9.8%, 
n=5; l-shMR: 100±5.3%, n=5) or another steroid receptor such 
as the glucocorticoid receptor (control: 100.0±7.7%, n=4; 
l-shMR: 90.9±8.9%, n=4), suggesting that the l-shMR vector 
specifically targeted the MR, minimizing the possibility of non-
specific effects. Consistent with the reduction in MR protein 
expression, hearts injected with l-shMR had an ≈55% reduc-
tion in MR mRNA abundance compared with those injected 
with the control vector (Figure 2C). Importantly, no changes 
in MR protein expression were detected either in the lung or 
in the liver of injected animals (Figure S3), supporting the idea 
that the presence of l-shMR was restricted to the myocardium. 
Similar results were obtained when this technique was used to 
silence the NHE1 by direct injection of a naked interference 
RNA in the left ventricular wall.10
Because we have previously shown that the SFR to myo-
cardial stretch is the mechanical counterpart of an autocrine/
paracrine mechanism triggered by the release of endogenous 
angiotensin II (Ang II) involving MR and NHE1 activation,11 
we decided to functionally test the MR under our experimen-
tal conditions by exploring the SFR and NHE1 activation 
after stretching isolated papillary muscles from l-shMR– and 
control-injected hearts. The stretching of the papillary mus-
cles in the control group promoted the characteristic biphasic 
mechanical response, an initial abrupt force increase followed 
by the SFR (Figure 3A–3C). On the contrary, the SFR was 
absent in the papillary muscles isolated from MR-silenced 
hearts (Figure 3B and 3C).
Alkalization of cardiac muscle in bicarbonate-free medium 
is a key signal of stretch-triggered NHE1 activation12; there-
fore, we next determined pH
i
 changes after stretching isolated 
papillary muscles from both experimental groups. As expected, 
a significant increase in pH
i
 was detected in papillary muscles 
from control-injected hearts, whereas no pH
i
 changes were 
observed in the l-shMR–injected group as shown in Figure 4, 
revealing the absence of stretch-induced NHE1 activation. The 
results shown in Figures 3 and 4 indicate that MR activation 
Figure 1. Myocardial patchy distribution of the lentivirus. 
A, Representative confocal images of lentiviral vector (l-shMR)–
injected (top), scramble-injected (middle), and sham-operated 
(bottom) rat myocardium. Samples of the myocardium were 
serially sectioned using a vibratome. The first column shows 
the DsRed fluorescence. The second column presents the 
captured myocardial area using differential interference contrast 
(DIC). The third column represents the merging of the previous 
images. Different intensities of DsRed expression and a patchy 
distribution could be appreciated in the first and second rows. 
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is crucial to NHE1 stimulation and the SFR development after 
myocardial stretching, as reported previously based on phar-
macological interventions.1
Myocardial stretch induces NHE1 phosphorylation at 
Ser70313 through a mechanism that involves redox-induced 
activation of ERK1/2 and p90RSK.13,14 As expected, we detected 
a significant increase in ERK1/2 and p90RSK phosphorylation 
after stretching control-injected papillary muscles, an effect 
that was considerably blunted in muscles from MR-silenced 
hearts (Figure 5). Therefore, an activated MR is a necessary 
condition to induce redox-sensitive kinase activation after 
myocardial stretch.
As we have already mentioned, myocardial stretching 
induces the activation of the Ang II AT1 receptor, trigger-
ing a chain of autocrine/paracrine intracellular signals that 
through the activation of the epidermal growth factor receptor 
(EGFR) leads to increased mitochondrial ROS production 
and activation of redox-sensitive kinases (Figure 5).13 To 
further characterize the signals upstream of these kinases, 
measurement of myocardial O
2
˙ production after a low 
concentration of Ang II (1 nmol/L), which was previously 
shown to mimic the increase in force observed during the 
SFR,15 was compared in tissue slices obtained from con-
trol- and l-shMR–injected hearts. Figure 6 shows that Ang 
II increased O
2
˙ production by ≈50% in the control group, 
whereas this effect was not observed in the myocardial slices 
from MR-silenced hearts. However, when an equipotent con-
centration of EGF (0.1 μg/mL) was used to stimulate O
2
˙ 
Figure 2. Mineralocorticoid receptor (MR) protein and mRNA 
expression in ventricular myocardium and papillary muscles. Hearts 
injected with lentiviral vector (l-shMR) designed to specifically 
downregulate MR expression showed a significant reduction in the 
amount of receptor protein compared with the scramble-injected 
hearts as shown in the representative original Western blot and 
in the averaged results of A (left ventricular homogenates) and 
B (papillary muscles). Consistently, hearts injected with l-shMR 
had an ≈55% reduction in MR mRNA abundance compared with 
scramble-injected heart. *P<0.05 vs scramble (C).
Figure 3. Slow force response (SFR) and mineralocorticoid 
receptor (MR) activation. A, Original force record of a papillary 
muscle from a scramble-injected rat heart subjected to an 
increase in length from 92% to 98% of Lmax, where it can be 
appreciated the classical biphasic response to stretch. B, Same 
as A but of a papillary muscle from a lentiviral vector (l-shMR)–
injected rat heart where the SFR was suppressed. C, Averaged 
SFR expressed as percentage of the initial rapid phase from both 
groups of animals. *P<0.05 scramble vs l-shMR.
Figure 4. Intracellular pH changes after stretch in isolated 
papillary muscles bathed with bicarbonate-free solution. As 
expected, myocardial stretch increased pHi in papillary muscles 
from scramble-injected hearts demonstrating the stretch-
triggered Na+/H+ exchanger activation, an effect that was not 
detected in muscles from lentiviral vector (l-shMR)–injected 
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formation, MR silencing did not abrogate the increase in O
2
˙ 
production observed in the control group (Figure 6), sug-
gesting that the MR is located downstream of the AT1 but 
upstream of the EGFR in the mitochondrial ROS formation 
pathway. Taken together, these data unequivocally support 
that MR activation after myocardial stretch is an important 
event upstream of myocardial ROS production and ERK1/2, 
p90RSK, and NHE1 activation.
Discussion
In the present study, a gene-silencing strategy with small 
interfering RNA was used to specifically downregulate MR 
protein expression in the rat myocardium. This approach 
reduced MR mRNA and protein expression to approximately 
half in homogenates of the whole left ventricle, as well as in 
the papillary muscles used for functional studies, an effect 
that was enough to blunt the stretch-triggered activation of 
redox-sensitive kinases upstream of the NHE1 and its down-
stream effects. These results come to extend the relevance of 
our previous report using eplerenone to prevent MR activa-
tion after stretch1 by providing strong support for the notion 
that MR activation is a consequence of the intracellular sig-
nals triggered by myocardial stretch. The effectiveness of the 
technique used to silence the myocardial MR seems to be 
related to the spread of the shMR from cell to cell through 
connexins, as proposed by Kizana et al.16 Furthermore, we 
successfully used this same methodology in a previous work 
to knockdown the NHE1 expression in rat hearts.4 In addi-
tion, Gupta et al17 used this technique to silence nuclear 
factor-κβ, and Schuman et al18 used this technique to iden-
tify the key role of cardiac thyrotropin-releasing hormone 
in mediating left ventricular hypertrophy in spontaneously 
hypertensive rats.
The reduction in MR expression at both the protein and 
mRNA levels found in homogenates of the whole left ventri-
cle of l-shMR–injected hearts was only partial but sufficient 
to completely prevent the stretch-induced functional effects, 
proving the effectiveness of the MR-silencing procedure. The 
modest decrease in MR protein expression that we detected 
could possibly be a result of insufficient delivery of the len-
tiviral-transducing units. However, as quoted before, a com-
plete functional inactivation of the receptor was observed. 
Whether this effect represents a characteristic of MR func-
tion, in which 50% of a decrease in the functional units is 
enough to achieve complete cancellation of the increase in 
ROS production and its downstream effects, is not apparent 
to us at this moment.
A link between Ang II or its AT1 receptor and the MR has 
been reported previously.19–21 In connection with this, the 
release of preformed Ang II by the cardiomyocytes after stretch 
was proved in elegant experiments by Sadoshima et al22 and 
later on by Leri et al.23 In addition, Browe and Baumgarten24 
proposed a mechanotransduction model explaining the 
release of Ang II after stretch, where β1 integrin activation 
may conceivably be the link between membrane deforma-
tion and the release of endogenous Ang II. However, we have 
previously shown that AT1 receptor blockade with losartan 
blunts the SFR to stretch,2,3 and this mechanical effect can 
Figure 6. Myocardial superoxide anion production induced 
by angiotensin II (Ang II) or epidermal growth factor. Ang II 
increased O2˙ production by ≈50% of control in the myocardium 
of scramble-injected hearts, an effect that was canceled in the 
mineralocorticoid receptor (MR)–silenced group. This result 
indicates that Ang II requires the activation of the MR to promote 
an increase in O2˙ production in the myocardium. In contrast, 
when epidermal growth factor (EGF) was used to stimulate O2˙ 
formation, the increase in O2˙ production was observed in both 
experimental groups, indicating that in the route of reactive 
oxygen species formation the MR is located upstream of the 
EGF receptor. Results are expressed as percentage of the 
corresponding control (scramble or lentiviral vector [l-shMR]) 
without interventions. *P<0.05 vs control scramble, #P<0.05 vs 
control l-shMR.
Figure 5. ERK1/2 and p90RSK phosphorylation 
after stretch. The stretch of scramble-injected 
papillary muscles significantly increased ERK1/2 
(A) and p90RSK (B) phosphorylation expressed 
as percentage of nonstretched muscles, effect 
that was significantly blunted in papillary 
muscles from lentiviral vector (l-shMR)–injected 
hearts. Representative Western blots (top) and 
averaged P-ERK1/2 or P-p90RSK to GAPDH 
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be mimicked by a low concentration of exogenous Ang II15 
(within the concentration range reported to be released after 
myocyte stretching by Sadoshima and Izumo).22 In the pres-
ent study, we show that the Ang II–promoted increase in ROS 
production is also canceled in the MR-silenced myocardium, 
which is in line with previous reports in smooth and cardiac 
muscles.1,21 However, increased ROS formation in response 
to EGF was preserved in the myocardium where the MR 
expression was downregulated. This suggests that in the 
chain of intracellular signals after myocardial stretch, the role 
of the MR is upstream of the EGFR and that MR activation 
is necessary to stimulate the downstream functional effects, 
confirming our previous findings using either pharmacologi-
cal inhibition of the MR or a metalloproteinase inhibitor to 
prevent MR-dependent EGFR transactivation.1 Furthermore, 
these results reinforce the notion that EGFR transactivation 
occurs via the MR1 and not directly through a G protein–
coupled receptor as we proposed previously.13 The fact that 
EGFR transactivation can be triggered by MR activation was 
recognized previously by others.19,25,26 EGFR transactivation 
seems to be performed by metalloproteinase-dependent cleav-
age of proheparin-binding EGF, which promotes ectoshed-
ding of heparin-binding EGF.27,28 Heparin-binding EGF is a 
well-known ligand of EGFR, and binding of heparin-binding 
EGF to EGFR leads to activation of the receptor by tyrosine 
autophosphorylation. Once EGFR is phosphorylated, the 
downstream signals increase mitochondrial O
2
˙ production. 
Figure 7 illustrates our hypothesis in which transactivation 
takes place after metalloproteinase activation subsequent to 
MR stimulation.
In the present study, we did not explore the mechanism 
by which myocardial MR becomes activated after stretching. 
Aldosterone synthesis by the cardiac myocyte is unlikely 
in light of previous reports showing that the heart has no 
or extremely low mRNA of aldosterone synthase and 
11-β-hydroxilase.29–31 However, myocardial aldosterone was 
detected in 30% of hearts from adrenalectomized rats,29 sug-
gesting that the heart is probably able to synthesize small 
amounts of aldosterone. In any case, aldosterone uptaken 
by the heart from the circulation, synthesized by the heart, 
or a combination of both could be released after stretch. 
It is important to keep in mind that Ang II is the primary 
stimulus for aldosterone production from the adrenal glands, 
and pharmacological amounts of exogenous Ang II were 
reported to increase the aldosterone concentration in the 
heart and serum.32
The MR is overexpressed in heart failure,33,34 and the clini-
cal efficacy of MR inhibitors in the treatment of heart failure 
has been well established.35–37 However, the exact mecha-
nisms by which MR antagonists provide cardiovascular pro-
tection in patients with cardiac failure are not completely 
understood. From a simplistic point of view, it may be rea-
soned that elevated circulating levels of aldosterone, resulting 
in activation of MR in different tissues, could be detrimental; 
therefore, MR blockade would be beneficial. However, this 
argument is challenged by the fact that the beneficial effects 
of MR antagonism are observed even at normal circulating 
levels of aldosterone35,38–40 and are independent of natriuretic 
effects.35,39,40 Furthermore, under normal conditions without 
an increase in oxidative stress, the MR is occupied but not 
activated by glucocorticoids.
As we reported previously1 and confirm here in the con-
trol-injected hearts (Figure 6), MR activation increases 
ROS formation. Therefore, an expected consequence of 
Figure 7. Suggested sequence of events triggered by myocardial stretch. Mineralocorticoid receptor (MR) activation, probably by 
endogenous formation/release of aldosterone, seems to be located upstream of epidermal growth factor receptor (EGFR) activation 
in the chain of intracellular signals, leading to the slow force response. Therefore, EGFR transactivation seems to originate from MR 
and not from G protein–coupled receptor, as we suggested previously. EGFR transactivation seems to result from a metalloproteinase 
(MMPs)-promoted ectoshedding of heparin-binding EGF (HB-EGF), a known ligand of EGFR, which promotes receptor activation by 
tyrosine autophosphorylation, leading to mitochondrial reactive oxygen species formation, redox-sensitive kinase activation, and Na+/H+ 
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the increased oxidative stress should be the enhanced func-
tion of the NHE1, as we recently reported.41 Interestingly, 
a role for the NHE1 in heart failure was proposed by 
Baartscheer et al,42 who in elegant experiments showed that 
long-term NHE1 inhibition with cariporide decreased the 
augmented diastolic calcium without significant alteration 
in systolic calcium in rabbits with hypertrophy and failure. 
The decrease in diastolic calcium is probably sensed by 
the prohypertrophic phosphatase, calcineurin, whereas the 
increase in the calcium transient amplitude increases car-
diac inotropism.
Our data suggest that MR antagonism may be followed by 
inhibition of mitochondrial ROS formation and NHE1 activa-
tion, 2 known deleterious signals for the heart. Interestingly, 
these actions could be responsible, at least in part, for the sal-
utary effects of the MR inhibitors used clinically in heart fail-
ure,35–37 where an increase in oxidative stress takes place. Our 
results are in line with previous reports in mice in which abla-
tion of the MR in myocytes preserves cardiac function after 
chronic pressure overload43 and also decreases adverse car-
diac remodeling after myocardial infarction,44 2 pathological 
conditions in which the myocardium is stretched. A similar 
protection was obtained when mice deprived of myocardial 
MR were compared with their controls after treatment with 
deoxycorticosterone acetate/salt.45
Perspectives
There is growing evidence showing striking beneficial 
effects of MR blockade in the treatment of systolic heart 
failure, a condition in which cardiac muscle is stretched. 
Despite that these salutary effects have been well docu-
mented in 3 different clinical trials (RALES,35 EPHESUS,36 
and EMPHASIS37), the exact mechanism by which MR inac-
tivation improves heart failure is still not clear. In the pres-
ent study, by silencing cardiac MR expression, we confirmed 
its activation after myocardial stretch. MR activation is a 
step in a chain of events leading to EGFR transactivation, 
enhanced mitochondrial ROS production, redox-sensitive 
kinase activation, and NHE1 activation. We can speculate 
that the decrease in ROS formation after the deactivation of 
the MR-triggered signaling cascade may be responsible for 
at least part of the beneficial effects of the clinically used 
MR blockers in cardiac failure.35–37
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What Is New?
•	We report mineralocorticoid receptor (MR) activation after myocardial 
stretch.
What Is Relevant?
•	Because stretched myocardium is a characteristic of systolic heart fail-
ure in which an increase in oxidative stress occurs, silencing of the MR 
would be beneficial. Our data suggest that MR inhibition is followed by 
deactivation of mitochondrial reactive oxygen species formation and 
Na+/H+ exchanger stimulation, 2 known deleterious signals of the heart. 
These actions could be responsible, at least in part, for the salutary 
 effects of the MR inhibitors in patients with heart failure.
Summary
In this study, a gene-silencing strategy was used to specifically 
downregulate MR protein expression in the myocardium to spe-
cifically test the role of MR activation after stretch. Our findings 
provide strong evidence that MR activation occurs after myocardial 
stretch and is a key factor promoting redox-sensitive kinase activa-
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